Adopting extensive intra-operative peritoneal lavage (EIPL) as the standard prophylactic strategy for peritoneal recurrence

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 266-270

  Shimada, Shinya ^a   Kuramoto, Masafumi ^a   Marutsuka, Takashi ^b   Yagi, Yasushi ^c   Baba, Hideo ^d  

^a Yatsushiro Social Insurance General Hospital   (Japan)

^b KUMAMOTO CHUO HOSPITAL   (Japan)

^c Department of Surgery   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Clinical trial; EIPL; Gastric cancer; Intra peritoneal free cancer cells; Peritoneal recurrence; RT PCR; Survival

Indexed keywords

ADVANCED CANCER; CANCER CYTODIAGNOSIS; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; HUMAN; INTRAOPERATIVE PERIOD; PERITONEUM CANCER; PERITONEUM LAVAGE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER;

CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; HUMANS; KERATIN-20; NEOPLASM RECURRENCE, LOCAL; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; PERITONEUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 80051768237     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575603     Document Type: Review

References (63)

1. Balfour DC. Factors of significance in the prognosis of cancer of the stomach. Ann Surg 1973; 105: 733-40.
2. Maruyama K. The most important prognostic factors for gastric cancer patients. A study using univariate and multivariate analyses. Scand J gastroenterol 1987; 22: 63-8.
3. Yamamoto M, Matsuyama A, Kameyama T, et al. Prognostic reevaluation of peritoneal lavage cytology in Japanese patients with gastric carcinoma. Hepatogastroenterology 2009; 56: 261-5.
4. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010; 34: 555-62.
5. Makino T, Fujiwara Y, Takiguchi S, et al. The utility of preoperative peritoneal lavage examination in serosa-invading gastric cancer patients. Surgery 2010; 148: 96-102.
6. Iitsuka Y, Kaneshima S, Tanida O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 1979; 44: 1476-80.
7. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Hiraoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984; 108: 236-8.
8. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998; 16: 2681-6.
9. Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol 1998; 5: 411-5.
10. Ulysses R Jr, Adiana VS, Bruno Z, et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection? J Gastrointest Surg 2006; 10: 170-7.
11. Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 2003; 9: 678-85.
12. Kaibara N, Iitsuka Y, Kimura A, et al. Relationship between area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer 1987; 60: 136-9.
13. Moriguchi S, Maehara Y, Korenaga D, Sugiuchi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992; 1: 341-6.
14. Ikeguchi M, Oka A, Tsujitani S, Maeta M, Kaibara N. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res 1994; 14: 2131-4.
15. Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol 1995; 59: 226-9.
16. Ribeiro U Jr, Gama-Rodrigues JJ, Safatle-Ribeiro AV, et al. Prognostic significance of intraperitoneal free cancer cells obtained by laparoscopic peritoneal lavage in patients with gastric cancer. J Gastrointest Surg 1998; 2: 244-9.
17. Boku T, Nakane Y, Minoura T, et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 1990; 77: 436-9.
18. Shimada S, Yagi Y, Shiomori K, et al. Proposal of the optimal and practical therapeutic strategy for gastric cancer. In Biological Response to Planned and Unplanned injuries: Cellular, molecular and genetic aspects. Ogawa M, et al. Eds, International Congress Series, Elsevier, Amsterdam, 2003; 389-97.
19. Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-62.
20. Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989; 76: 1082-90.
21. Sauter T, Hofbauer F, Depisch D. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-4.
22. Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629-31.
23. Kunisaki C, Shimada H, Nomura M, Akiyama H, Takahashi M, Matsuda G. Lack of efficacy of prophylactic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery 2002; 131: 521-8.
24. Ikeguchi M, Matsumoto S, Yoshida S, et al. Laparoscopic-assisted intraperiotneal chemotherapy for the patients with scirrhous gastric cancer. Chemotherapy 2005; 51: 15-20.
25. Cheong JH, Shen JY, Song CS, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol 2007; 14: 61-8.
26. Shimada S, Tanaka E, Marutsuka T, et al. Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer 2002; 5: 168-72.
27. Yamamoto K, Shimada S, Hirota M, Yagi Y, Matsuda M, Baba H. EIPL(extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. Int J Oncol 2005; 27: 1321-8.
28. Kuramoto M, Shimada S, Tashima T, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009; 250: 242-6.
29. Bozzetti F, Bonfanti G, Morabito A, et al. A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg Gynecol Obstet 1986; 162: 229-34.
30. Fink A, Longmire W. Carcinoma of stomach. In: Subiston DC, eds. Textbook of Surgery, 14th ed. Philadelphia: WB Saunders; 1991: 814-27.
31. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-42.
32. Shimada S, Yagi Y, Shiomori K, et al. Characterization and proposal of the optimal therapeutic strategy for early gastric cancer. Surgery 2001; 129: 714-9.
33. Wu CC, Chen JT, Chang MC, et al. Optimal surgical strategy for potentially curable serosa-involved gastric carcinoma with intraperitoneal free cancer cells. J Am Coll Surg 1997; 184: 611-7.
34. Hayes N, Wayman J, Wadehra V, Scott DJ, Raimes SA, Griffin SM. Peritoneal cytology in the surgical evaluation of gastric carcinoma. Br J cancer 1999; 79: 520-4.
35. Fujimoto T, Zhang B, Minami S, Wang X, Takahashi Y, Mai M. Evaluation of intraoperative intraperitoneal cytology for advanced gastric carcinoma. Oncology 2002; 62: 201-8.
36. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16: 2733-8.
37. Hamazoe R., Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73: 2048-52.
38. Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 1995; 19: 1-6.
39. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-54.
40. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperiotneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-34.
41. Kodera Y, Yamamura Y, Shimizu Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-5.
42. Rosenberg R, Nekarda H, Bauer P, Schenck U, Hoefler H, Siewert JR. Free peritoneal tumor cells are an independent prognostic factor in curatively resected stage 1B gastric carcinoma. Br J Surg 2006; 93: 325-31.
43. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma, First English Editon. Tokyo: Kanehara; 1999.
44. Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992; 70: 1030-7.
45. Ohgaki M, Takahashi T, Hagiwara A, Yamasaki J, Togawa T. Effect of Extensive lymphnode dissection on the survival of early gastric cancer. Hepato-Gastroenterol 1999; 46: 2096-9.
46. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for nodenegative gastric cancer. J Gastrointest Surg 1998; 2: 126-31.
47. Shimada S, Yagi Y, Honmyo U, Shiomori K, Yoshida N, Ogawa M. Involvement of more than three lymph nodes predicts poor prognosis of early gastric carcinoma. Gastric Cancer 2001; 4: 54-9.
48. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-73.
49. Wu CW, Chiou JM, Ko FS, et al. Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 2008; 98: 54-9.
50. Zhang H, Liu C, Wu D, et al. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. BMC Cancer 2010; 10: 308.
51. Bonenkamp JJ, Songun I, Sasako M, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-8.
52. Suhsien L, Bart EM, Stuart GM, et al. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patients subgroups? J Surg Oncol 2007; 95: 118-22.
53. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000; 18: 315-29.
54. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999; 57: 202-10.
55. Ishizoe S, Maruta F, Saito H, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy 2006; 52: 301-7.
56. Papanicolaou GN. Atlas of Exfoliative Cytology. Cambridge: Harvard University Press; 1963.
57. Benevolo M, Mottolese M, Cosomelli M, et al. Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 1998; 16: 3406-11.
58. Vogel P, Ruschoff J, Kummel S, et al. Immunocytology improves prognostic impact of peritoneal tumour cell detection compared to conventional cytology in gastric cancer. Eur J Surg Oncol 1999; 25: 515-9.
59. Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95: 123-8.
60. Broll R, Weschta M, Windhoevel U, et al. Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction. Langenbeck's Arch Surg 2001; 386: 285-92.
61. Vogel I, Kalthoff H. Disseminated tumor cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchow Arch 2001; 439: 109-17.
62. Kodera Y, Nakanishi H, Ito S, et al. Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction. Ann Surg 2002; 235: 499-506.
63. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg 2006; 243: 64-73.